Expert Interview
A look at the developing landscape for children with achondroplasia including the Phase 3 PROPEL 3 data of oral infigratinib and the 52-week COACH data of TransCon CNP with TransCon hGH.
Ticker(s): ASND, BBIOInstitution: University Hospital Cologne
- Head of the Center for Rare Skeletal Disorders in Children and Adolescents at the University of Cologne & member of the Osteogenesis Imperfecta Federation Europe (OIFE) Medical Advisory Board
- Treats 60-70 patients with Achondroplasia older than 5 years of age and is currently prescribing Voxzogo to 26 patients.
- Specializes in the research of brittle bone disease and directs the special ambulance for rare pediatric skeletal diseases and pediatric rheumatology.
How many child patients do you manage with achondroplasia?
Added By: sara_adminOn a scale of 1 to 10 (with 10 being ecstatic), how excited are you for oral Infigratinib therapy as a potential treatment for children with achondroplasia?
Added By: sara_adminOn a scale of 1 to 10 (with 10 being ecstatic), how excited are about the 52-week COACH data of TransCon CNP with TransCon hGH and its potential as a treatment for children with achondroplasia?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Feb 19, 2026
- Call Time
- 10:00 AM EST
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
